54.25 +0.01 (0.01%)
After hours: 4:06PM EST
|Bid||54.25 x 1100|
|Ask||54.25 x 2200|
|Day's Range||54.12 - 54.60|
|52 Week Range||40.81 - 54.73|
|Beta (5Y Monthly)||0.77|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jan 28, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||55.70|
Hologic’s First Sustainability Report Highlights Global Corporate Citizenship Efforts in Fiscal 2019
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Hologic (HOLX) expects to generate robust Surgical and Diagnostics revenues in Q1, though softness in the divested Medical Aesthetics business remains a concern.
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China. If you were a passive index fund investor, you had seen gains of 31% in your equity portfolio in 2019. However, if you were an […]
Hologic to Announce Financial Results for the First Quarter of Fiscal 2020 on Wednesday, January 29, 2020
Hologic (HOLX) expects to witness favorable outcomes from the sell-off of the Cynosure medical aesthetics business, which was its loss-making arm since 2017.
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 13 at 8 a.m. Pacific Time.
We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]
Hologic, Inc. (HOLX) will showcase its comprehensive portfolio of breast and skeletal health products, including screening, interventional, surgical, ultrasound and skeletal solutions, in Booth #2511 at the 105th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) at McCormick Place in Chicago from Dec. 1 to 5. The world leader in mammography, Hologic continues to expand and strengthen its preeminent position in breast health, most recently ranking first in customer satisfaction, service and system performance on the 2019 IMV ServiceTrack™ Diagnostic Imaging report, an annual customer satisfaction survey on the medical imaging industry. Among mammography categories overall, Hologic tops the list for the fourth consecutive year, a testament to the Company’s ongoing dedication to insight-driven innovation, diagnostic leadership, product quality and service in women’s healthcare.
Clinical evidence demonstrating the effectiveness of new FDA-cleared assays for the detection of vaginitis has been published online in the Journal of Clinical Microbiology. The prospective, multi-center clinical study is the first in the United States to formally validate the performance of the Aptima® BV and Aptima® CV/TV assays, available from Hologic, Inc. (HOLX) on its fully automated Panther® system.